« Return to News | R&D Trends

Nuevolution launches collaboration

Monday, August 12, 2013 01:12 PM

Nuevolution is collaborating with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals for the investigation of the biological mechanism of action of a specified GPCR drug target. The Principal Investigator for Duke University and the Howard Hughes Medical Institute is Robert J. Lefkowitz, a Duke faculty member, HHMI employee and Nobel Laureate in Chemistry 2012.

Nuevolution will provide access to its proprietary Chemetics technology for small molecule drug discovery and Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics technology. Hundreds of millions of diverse small molecules will be screened to discover compounds with certain novel and unique properties against the GPCR drug target.

“We have used the Chemetics technology successfully to identify novel chemotypes for our internal programs and are enthusiastic about exploring the utility of our DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs,” said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer of Lexicon.

“If successful, this project may cast new light on the mechanism of action of GPCRs,” said Thomas Franch, chief scientific officer of Nuevolution.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.